PL4051249T4 - Kompozycja farmaceutyczna zawierająca mitotan do podawania doustnego do leczenia raka kory nadnerczy oraz zespołu Cushing’a - Google Patents

Kompozycja farmaceutyczna zawierająca mitotan do podawania doustnego do leczenia raka kory nadnerczy oraz zespołu Cushing’a

Info

Publication number
PL4051249T4
PL4051249T4 PL20786346.5T PL20786346T PL4051249T4 PL 4051249 T4 PL4051249 T4 PL 4051249T4 PL 20786346 T PL20786346 T PL 20786346T PL 4051249 T4 PL4051249 T4 PL 4051249T4
Authority
PL
Poland
Prior art keywords
cushing
mitotane
syndrome
treatment
pharmaceutical composition
Prior art date
Application number
PL20786346.5T
Other languages
English (en)
Other versions
PL4051249T3 (pl
Inventor
Malika Lahiani-Skiba
Frédéric BOUNOURE
Michael Thomas
Hervé LEFEBVRE
Mohamed Skiba
Original Assignee
Mohamed Skiba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mohamed Skiba filed Critical Mohamed Skiba
Publication of PL4051249T4 publication Critical patent/PL4051249T4/pl
Publication of PL4051249T3 publication Critical patent/PL4051249T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20786346.5T 2019-10-28 2020-10-01 Kompozycja farmaceutyczna zawierająca mitotan do podawania doustnego do leczenia raka kory nadnerczy oraz zespołu Cushing’a PL4051249T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1912084A FR3102356B1 (fr) 2019-10-28 2019-10-28 Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing
PCT/IB2020/059218 WO2021084345A1 (fr) 2019-10-28 2020-10-01 Composition pharmaceutique comprenant le mitotane pour une administration par voie orale pour le traitement du carcinome corticosurrenalien et du syndrome de cushing

Publications (2)

Publication Number Publication Date
PL4051249T4 true PL4051249T4 (pl) 2024-04-08
PL4051249T3 PL4051249T3 (pl) 2024-04-08

Family

ID=69810998

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20786346.5T PL4051249T3 (pl) 2019-10-28 2020-10-01 Kompozycja farmaceutyczna zawierająca mitotan do podawania doustnego do leczenia raka kory nadnerczy oraz zespołu Cushing’a

Country Status (16)

Country Link
US (1) US20240058277A1 (pl)
EP (1) EP4051249B1 (pl)
JP (1) JP2023500494A (pl)
KR (1) KR20220088904A (pl)
CN (1) CN114599347B (pl)
AU (1) AU2020377140A1 (pl)
CA (1) CA3153794A1 (pl)
ES (1) ES2966481T3 (pl)
FR (1) FR3102356B1 (pl)
HR (1) HRP20231641T1 (pl)
HU (1) HUE064738T2 (pl)
MX (1) MX2022004255A (pl)
PL (1) PL4051249T3 (pl)
RS (1) RS64962B1 (pl)
WO (1) WO2021084345A1 (pl)
ZA (1) ZA202205923B (pl)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146648A (en) * 1977-07-14 1979-03-27 Bristol-Myers Company Chemotherapeutic composition
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
JP2001354515A (ja) * 2000-06-14 2001-12-25 Shiseido Co Ltd 複合エマルジョン及びこれを配合した化粧料
FR2825714B1 (fr) * 2001-06-08 2005-03-25 Seppic Sa Nouvelle utilisation de complexes d'inclusion de cyclodestrine
JP5403585B2 (ja) * 2006-01-23 2014-01-29 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 活性薬剤用のデリバリーシステム
FR2944699A1 (fr) * 2009-04-23 2010-10-29 Centre Nat Rech Scient Procede de formation d'emulsions a base de polymeres de cyclodextrine et de composes lipophiles, emulsions ainsi obtenues, et compositions comprenant lesdites emulsions
EP2255786A1 (en) * 2009-05-25 2010-12-01 HRA Pharma LLC Self-microemulsifying mitotane composition
US20130317117A1 (en) 2010-11-24 2013-11-28 Pharmaceutics International, Inc. Self micro-emulsifying drug delivery system with increased bioavailability
CN105250221B (zh) * 2014-07-14 2018-06-19 天津药物研究院 一种利可瑞特干乳剂及其制备方法
CN105395492B (zh) * 2015-11-23 2018-05-25 河南大学 一种挥发油固体自乳化片剂及其制备方法

Also Published As

Publication number Publication date
EP4051249B1 (fr) 2023-09-13
US20240058277A1 (en) 2024-02-22
EP4051249C0 (fr) 2023-09-13
HRP20231641T1 (hr) 2024-03-15
CA3153794A1 (en) 2021-05-06
MX2022004255A (es) 2022-05-06
AU2020377140A1 (en) 2022-06-09
CN114599347B (zh) 2024-07-12
FR3102356B1 (fr) 2021-09-17
WO2021084345A1 (fr) 2021-05-06
RS64962B1 (sr) 2024-01-31
KR20220088904A (ko) 2022-06-28
PL4051249T3 (pl) 2024-04-08
EP4051249A1 (fr) 2022-09-07
HUE064738T2 (hu) 2024-04-28
CN114599347A (zh) 2022-06-07
ZA202205923B (en) 2023-04-26
JP2023500494A (ja) 2023-01-06
FR3102356A1 (fr) 2021-04-30
ES2966481T3 (es) 2024-04-22

Similar Documents

Publication Publication Date Title
IL270812B1 (en) Solid preparations for oral administration containing semaglutide and dapagliflozin and their use in medicine
IL314347A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
PL3829628T3 (pl) Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5
IL285073B2 (en) Liquid concentrated pharmaceutical preparations of furosemide and methods of administering these preparations
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL271013B (en) Allosteric egfr inhibitors with a modified isoindole, pharmaceutical preparations containing them and their use in medical treatment and/or preventive treatment of cancer
HUE063383T2 (hu) Folyékony készítmény az oro-faringo-laringo-özofageális traktus nyálkahártyájának kezelésében történõ felhasználásra
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
PL4051249T4 (pl) Kompozycja farmaceutyczna zawierająca mitotan do podawania doustnego do leczenia raka kory nadnerczy oraz zespołu Cushing’a
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
GB201910294D0 (en) Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine phosphate
PL3768246T3 (pl) Kompozycje farmaceutyczne sapozyny c i ich zastosowanie w leczeniu nowotworu
EP3458031A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF CELECOXIB AND THEIR USE IN THE TREATMENT OF CELCOXIB-SENSITIVE DISEASES AND CONDITIONS
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases
PL4188359T3 (pl) Kombinacja leków i jej zastosowanie w leczeniu raka
PL3813843T3 (pl) Kompozycja do stosowania w zapobieganiu i/lub leczeniu chorób układu kostno-stawowego
HK40031514A (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
CA3292080A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
HK40036525A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
HK40030474A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases